Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$11.54 USD
-0.10 (-0.86%)
Updated Jul 26, 2024 01:54 PM ET
After-Market: $11.52 -0.02 (-0.17%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth C Momentum F VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/1/24 |
---|---|
Current Quarter | -6.70 |
EPS Last Quarter | -5.98 |
Last EPS Surprise | -406.78% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -28.11 |
Next Year | -1.00 |
EPS (TTM) | -616.67 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.64M | 0.24M | 1.92M | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -6.70 | -8.80 | -28.11 | -1.00 |
# of Estimates | 1 | 1 | 1 | 1 |
Most Recent Consensus | NA | NA | NA | NA |
High Estimate | -6.70 | -8.80 | -28.11 | -1.00 |
Low Estimate | -6.70 | -8.80 | -28.11 | -1.00 |
Year ago EPS | -140.48 | -26.19 | -114.00 | -28.11 |
Year over Year Growth Est. | 95.23% | 66.40% | 75.34% | 96.44% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 1 | 1 | 1 | 1 |
Down Last 60 Days | 1 | 1 | 1 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -6.70 | -8.80 | -28.11 | -1.00 |
7 Days Ago | -6.70 | -8.80 | -28.11 | -1.00 |
30 Days Ago | -0.19 | -0.36 | -0.91 | -0.97 |
60 Days Ago | -0.19 | -0.36 | -0.91 | -0.97 |
90 Days Ago | -0.19 | -0.36 | -0.91 | -0.97 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -6.70 | -8.80 | -28.11 | -1.00 |
Zacks Consensus Estimate | -6.70 | -8.80 | -28.11 | -1.00 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -5.98 | NA | -26.19 | -140.48 | NA |
Estimate | -1.18 | NA | -261.90 | -214.29 | NA |
Difference | -4.80 | NA | 235.71 | 73.81 | 101.57 |
Surprise | -406.78% | NA | 90.00% | 34.44% | -94.11% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more